{"id":394678,"date":"2020-12-07T15:35:13","date_gmt":"2020-12-07T20:35:13","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=394678"},"modified":"2020-12-07T15:35:13","modified_gmt":"2020-12-07T20:35:13","slug":"philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\/","title":{"rendered":"Philip Morris International Announces U.S. Food and Drug Administration Authorization of IQOS 3 for Sale in the United States"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Philip Morris International Announces U.S. Food and Drug Administration Authorization of <i>IQOS 3<\/i> for Sale in the United States <\/b><\/p>\n<p>NEW YORK&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nThe U.S. Food and Drug Administration (FDA) today confirmed that <i>IQOS 3<\/i>, Philip Morris International\u2019s electrically heated tobacco system, is appropriate for the protection of public health and has authorized it for sale in the United States. FDA\u2019s decision follows an assessment of a premarket tobacco product application (PMTA) filed with the agency in March 2020.\n<\/p>\n<p>\nThe <i>IQOS 3<\/i> device contains a number of technological advancements, compared to a previously authorized <i>IQOS<\/i> device, including longer battery life and quicker recharge between uses.\n<\/p>\n<p>\nIn its <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F144187%2Fdownload&amp;esheet=52344271&amp;newsitemid=20201207005912&amp;lan=en-US&amp;anchor=decision&amp;index=1&amp;md5=8dc723375aaafdc3662a512bb4a918c0\">decision<\/a> the FDA noted that:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nInternational survey data reviewed by the agency found no evidence of increased uptake of <i>IQOS<\/i> by youth or young adults, while use patterns available for a previously authorized version of <i>IQOS<\/i> within the U.S. have not raised new concerns regarding product use in youth and young adults.\n<\/li>\n<\/ul>\n<p>\nCommenting on the FDA\u2019s announcement, Andr\u00e9 Calantzopoulos, PMI\u2019s Chief Executive Officer, said:\n<\/p>\n<p>\n\u201cThe agency\u2019s decision to authorize <i>IQOS 3<\/i> for sale in the U.S. is another important step forward for the tens of millions of American men and women who currently smoke. In just five years, approximately 11.7 million people around the world have stopped smoking and switched to <i>IQOS<\/i>, and we believe bringing a more modern version of <i>IQOS<\/i> to the U.S. will only accelerate switching by adults who smoke.\u201d\n<\/p>\n<p>\nHe added, \u201cThe order is subject to the same comprehensive commercialization requirements set in the April 2019 PMTA marketing orders for <i>IQOS 2.4,<\/i> which aim to maximize the opportunity for adults to switch from cigarettes, while minimizing unintended use. We, along with our licensee Altria, are committed to guarding against unintended use and fully support FDA\u2019s focus on protecting youth.\u201d\n<\/p>\n<p><b>Editor\u2019s Note: <\/b><\/p>\n<p>\nOn July 7, 2020, the FDA <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-authorizes-marketing-iqos-tobacco-heating-system-reduced-exposure-information&amp;esheet=52344271&amp;newsitemid=20201207005912&amp;lan=en-US&amp;anchor=authorized&amp;index=2&amp;md5=be7240e93feaea3606ba754f33f88e06\">authorized<\/a><i>IQOS 2.4<\/i> as a modified risk tobacco product (MRTP), finding that an <i>IQOS<\/i> exposure modification order is appropriate to promote the public health.\n<\/p>\n<p>\nThe <i>IQOS<\/i> 3 PMTA authorization is independent of the MRTP authorization for the <i>IQOS<\/i> 2.4 device. PMI expects to file an application seeking a modified exposure marketing order for the<i> IQOS<\/i> 3 device.\n<\/p>\n<p>\nOn April 30, 2019, the FDA <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-permits-sale-iqos-tobacco-heating-system-through-premarket-tobacco-product-application-pathway&amp;esheet=52344271&amp;newsitemid=20201207005912&amp;lan=en-US&amp;anchor=authorized&amp;index=3&amp;md5=56ce95a972bc2be6dadb20c806e4c233\">authorized<\/a><i>IQOS<\/i><i>2.4 <\/i>for sale in the U.S. through issuance of premarket tobacco authorization marketing orders.\n<\/p>\n<p><i>IQOS<\/i> is available in the U.S. market through an exclusive license with Altria Group, Inc<b>.<\/b><\/p>\n<p><b>Philip Morris International: Delivering a Smoke-Free Future <\/b><\/p>\n<p>\nPhilip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships a version of its <i>IQOS<\/i> Platform 1 device and its consumables to Altria Group, Inc. for sale under license in the U.S., where the U.S. Food and Drug Administration (FDA) has authorized their marketing as a modified risk tobacco product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI\u2019s smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of September 30, 2020, PMI estimates that approximately 11.7 million adult smokers around the world have already stopped smoking and switched to PMI\u2019s heat-not-burn product, available for sale in 61 markets in key cities or nationwide under the <i>IQOS<\/i> brand. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.pmi.com&amp;esheet=52344271&amp;newsitemid=20201207005912&amp;lan=en-US&amp;anchor=www.pmi.com&amp;index=4&amp;md5=419a2043bb5862702445c630d4b2563d\">www.pmi.com<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.pmiscience.com&amp;esheet=52344271&amp;newsitemid=20201207005912&amp;lan=en-US&amp;anchor=www.pmiscience.com&amp;index=5&amp;md5=1b9bcb88e19d8fb8c978a97283abe6ca\">www.pmiscience.com<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201207005912r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201207005912\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201207005912\/en\/<\/a><\/span><\/p>\n<p>\nCorey Henry<br \/>\n<br \/>Philip Morris International<br \/>\n<br \/>T. +41 (0)58 242 4500<br \/>\n<br \/>E. <a rel=\"nofollow\" href=\"mailto:corey.henry@pmi.com\">corey.henry@pmi.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> New York United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Tobacco FDA Retail Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201207005912\/en\/132893\/3\/logo_PMI.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Philip Morris International Announces U.S. Food and Drug Administration Authorization of IQOS 3 for Sale in the United States NEW YORK&#8211;(BUSINESS WIRE)&#8211; The U.S. Food and Drug Administration (FDA) today confirmed that IQOS 3, Philip Morris International\u2019s electrically heated tobacco system, is appropriate for the protection of public health and has authorized it for sale in the United States. FDA\u2019s decision follows an assessment of a premarket tobacco product application (PMTA) filed with the agency in March 2020. The IQOS 3 device contains a number of technological advancements, compared to a previously authorized IQOS device, including longer battery life and quicker recharge between uses. In its decision the FDA noted that: International survey data reviewed by the agency found no &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Philip Morris International Announces U.S. Food and Drug Administration Authorization of IQOS 3 for Sale in the United States&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-394678","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Philip Morris International Announces U.S. Food and Drug Administration Authorization of IQOS 3 for Sale in the United States - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Philip Morris International Announces U.S. Food and Drug Administration Authorization of IQOS 3 for Sale in the United States - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Philip Morris International Announces U.S. Food and Drug Administration Authorization of IQOS 3 for Sale in the United States NEW YORK&#8211;(BUSINESS WIRE)&#8211; The U.S. Food and Drug Administration (FDA) today confirmed that IQOS 3, Philip Morris International\u2019s electrically heated tobacco system, is appropriate for the protection of public health and has authorized it for sale in the United States. FDA\u2019s decision follows an assessment of a premarket tobacco product application (PMTA) filed with the agency in March 2020. The IQOS 3 device contains a number of technological advancements, compared to a previously authorized IQOS device, including longer battery life and quicker recharge between uses. In its decision the FDA noted that: International survey data reviewed by the agency found no &hellip; Continue reading &quot;Philip Morris International Announces U.S. Food and Drug Administration Authorization of IQOS 3 for Sale in the United States&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-07T20:35:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201207005912r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Philip Morris International Announces U.S. Food and Drug Administration Authorization of IQOS 3 for Sale in the United States\",\"datePublished\":\"2020-12-07T20:35:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\\\/\"},\"wordCount\":717,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201207005912r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\\\/\",\"name\":\"Philip Morris International Announces U.S. Food and Drug Administration Authorization of IQOS 3 for Sale in the United States - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201207005912r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-07T20:35:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201207005912r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201207005912r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Philip Morris International Announces U.S. Food and Drug Administration Authorization of IQOS 3 for Sale in the United States\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Philip Morris International Announces U.S. Food and Drug Administration Authorization of IQOS 3 for Sale in the United States - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\/","og_locale":"en_US","og_type":"article","og_title":"Philip Morris International Announces U.S. Food and Drug Administration Authorization of IQOS 3 for Sale in the United States - Market Newsdesk","og_description":"Philip Morris International Announces U.S. Food and Drug Administration Authorization of IQOS 3 for Sale in the United States NEW YORK&#8211;(BUSINESS WIRE)&#8211; The U.S. Food and Drug Administration (FDA) today confirmed that IQOS 3, Philip Morris International\u2019s electrically heated tobacco system, is appropriate for the protection of public health and has authorized it for sale in the United States. FDA\u2019s decision follows an assessment of a premarket tobacco product application (PMTA) filed with the agency in March 2020. The IQOS 3 device contains a number of technological advancements, compared to a previously authorized IQOS device, including longer battery life and quicker recharge between uses. In its decision the FDA noted that: International survey data reviewed by the agency found no &hellip; Continue reading \"Philip Morris International Announces U.S. Food and Drug Administration Authorization of IQOS 3 for Sale in the United States\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-07T20:35:13+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201207005912r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Philip Morris International Announces U.S. Food and Drug Administration Authorization of IQOS 3 for Sale in the United States","datePublished":"2020-12-07T20:35:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\/"},"wordCount":717,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201207005912r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\/","name":"Philip Morris International Announces U.S. Food and Drug Administration Authorization of IQOS 3 for Sale in the United States - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201207005912r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-07T20:35:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201207005912r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201207005912r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/philip-morris-international-announces-u-s-food-and-drug-administration-authorization-of-iqos-3-for-sale-in-the-united-states\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Philip Morris International Announces U.S. Food and Drug Administration Authorization of IQOS 3 for Sale in the United States"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/394678","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=394678"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/394678\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=394678"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=394678"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=394678"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}